Business Information
The group's principal activity is to develop and commercialize therapies for solid tumors, hematological malignancies and blood disorders. The group's products include Orathecintm (Rubitecan) capsules, Dacogentm (Decitabine) injection and Nipent(R) (Pentostatin for injection). The other products include generic anti-cancer products used for the treatment of solid tumors and acute leukemias. Non-pharmaceutical product includes surface safe, a two-step disposable towelette cleaning system used to decontaminate work surfaces where chemotherapeutic preparation is conducted. Formulation products are used for solid tumors, neoplastic meningitis and bone marrow transplant. The products are marketed mainly to cancer hospitals, clinics, private practice oncology clinics, oncology distributors and drug wholesalers in the United States.
|
|
Name |
Title
|
Email
|
| Allan Goldberg | Dir., Chmn. - Scientific Advisory Board | N/A | | James Manuso | Chmn., CEO, Pres. | N/A | | Mark Lewis | MD - Eurogen | N/A | | Gregory Berk | Chief Medical Officer | N/A | | Michael Molkentin | CFO, Corp. Sec. | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 38,083 | (16,487) | | 2005 | 30,169 | (14,482) | | 2004 | 31,993 | (46,860)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
